Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
Noosa News12 hours agoWoman rescued from car on Samford Road, Ferny Hills
-
Noosa News12 hours agoWoman injured after army truck rollover north-west of Brisbane
-
Noosa News12 hours agoFire crews battle blaze at two-storey home in Coorparoo
-
General22 hours agoMillions of red crabs begin annual migration on Christmas Island as numbers ‘skyrocket’